-+ 0.00%
-+ 0.00%
-+ 0.00%

J&J: JOHNSON & JOHNSON REPORTS 73% PSA RESPONSE RATE WITH INVESTIGATIONAL PASRITAMIG-BASED IMMUNOTHERAPY COMBINATION IN ADVANCED PROSTATE CANCER

Reuters·11/09/2026 13:58:04